Immunotherapy for mesothelioma treatment

Last Updated on 22nd September 2020 by Kirsty Smithson

Immunotherapy treatment for mesothelioma gives patients new hope

Researchers have identified a promising new delivery method for an immunotherapy combination that could aid mesothelioma treatment significantly.

The team of researchers from the University of North Carolina Lineberger Comprehensive Cancer Center say they discovered this by binding two molecules together.

Their research found that using nanoparticles to deliver multiple immunotherapy drugs at the same time increased the effectiveness of the treatment for mesothelioma.

This approach proved to be far more effective in awakening the body’s immune system to begin fighting the cancer.

Andrew Z. Wang, MD, associate professor in the UNC School of Medicine Department of Radiation Oncology said, “Our study suggests that if you’re able to present two different therapeutics at the same time to immune cells to help them fight cancer, the effect is greater.”

UNC researchers bound together a checkpoint inhibitor, a drug that spurs the T-cells to kill cancer cells, and OX40, a new class of immunotherapy, along with a dose of radiation, into a nanoparticle, and then directed it to a tumor.

This combination was found to stimulate the T-cells at higher rates than antibodies delivered separately.

In melanoma mouse models, the researchers witnessed a cure rate of 30 percent.

Promising new research using immunotherapy for mesothelioma treatment - nanoparticles
Nanoparticles loaded with dual immunotherapy cells

Immunotherapy is evolving as an effective treatment

Immunotherapy is still a relatively new treatment, but it has already shown to be effective in some lung cancer patients, including mesothelioma.

But as not all patients are responsive to immunotherapy, scientists continue their research into improving the effectiveness of what is considered a promising treatment.

As such, a very similar study was conducted last year by the National Cancer Institute.

Scientists wanted to assess the impact the sequence of immunotherapy drug delivery has on survival.

Using a PD-1 inhibitor and an OX40 drug, they found that when the OX40 was delivered first that the treatment was more effective.

Together, both studies show that immunotherapy treatment used in combination with other inhibitors, and simultaneous delivery is a step forward in new effective mesothelioma treatment for patients.

Did you find this article on immunotherapy for mesothelioma treatment interesting? Then check out our other articles below.

Duty holders and employers have a legal responsibility to manage asbestos in their properties, carrying out an asbestos survey in their building so as not to put employees at risk.

So make sure you contact our Armco office to arrange an asbestos survey, before it’s too late! 

Whether you need an asbestos management survey, or a refurbishment/ demolition survey, contact us on 0161 763 3727 or by visiting

Finally, for all your asbestos training needs call 0161 761 4424 or visit book an asbestos awareness training course.

Published May 08, 2018

Get in touch

Skip to toolbar